Research programme: respiratory syncytial virus vaccines - NanoBio

Drug Profile

Research programme: respiratory syncytial virus vaccines - NanoBio

Alternative Names: Nanoemulsion adjuvanted intramuscular RSV vaccine - NanoBio; Nanoemulsion adjuvanted intranasal RSV vaccine - NanoBio

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator NanoBio Corporation
  • Class Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 27 Dec 2016 Preclinical development is ongoing for Respiratory-syncytial-virus-infections (Prevention) in USA (Intranasal) (NanoBio's pipeline, December 2016)
  • 19 Dec 2016 NanoBio has patent protection for nano-emulsion respiratory syncytial virus vaccines in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(Prevention) in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top